- Autores: Barros MT, Faisca Phillips AM, Murtinheira F, Nogueira F
- Ano de Publicação: 2015
- Journal: Bioorganic & Medicinal Chemistry Letters
- Link: http://www.ncbi.nlm.nih.gov/pubmed/25881827
The continuous development of drug resistance by Plasmodium falciparum, the agent responsible for the most severe forms of malaria, creates the need for the development of novel drugs to fight this disease. Fosmidomycin is an effective antimalarial and potent antibiotic, known to act by inhibiting the enzyme 1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), essential for the synthesis of isoprenoids in eubacteria and plasmodia, but not in humans.